CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 295 enrolled
Drug / intervention
5mg Serlopitant Tablets +1 moredrug
Likely dose
5mg Serlopitant Tabletsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03677401
NCT03677401Phase 3Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis

Vyne Therapeutics Inc.·interventional·Posted Sep 19, 2018·Updated May 20, 2021

In Brief

A Phase 3 clinical trial evaluating 5mg Serlopitant Tablets and Placebo Tablets for Pruritus and Prurigo Nodularis. Completed, enrolled 295 participants across 40 sites in 3 countries.

Detailed Summary

Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPruritus, Prurigo Nodularis
CountriesAustria, Germany, Poland
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedSep 19, 2018
Enrollment StartAug 29, 2018
Primary CompletionJan 9, 2020
Study CompletionFeb 6, 2020
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 7.8 years ago

Interventions

5mg Serlopitant Tabletsdrug

Serlopitant Tablets

Placebo Tabletsdrug

Placebo Tablets